Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/2040622315620180 http://scihub22266oqcxt.onion/10.1177/2040622315620180 C4772342!4772342!26977279     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ther+Adv+Chronic+Dis 2016 ; 7 (2): 92-107 Nephropedia Template TP {{tp|p=26977279|t=2016. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity |pdf=|usr=}}{{26977279}} gab.com Text The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity JO: Ther Adv Chronic Dis http://www.kidney.de/pget.php?&tw=1&pmid=26977279 #FOAvip There is a global obesity epidemic that will continue to be a financial burden on healthcare systems around the world. Tackling obesity through diet and exercise should always be the first intervention, but this has not proved to be effective for a large number of patients. Pharmacotherapeutic options have been limited and many previously available drugs have been withdrawn due to safety concerns. Currently, only bariatric surgery has the capability to induce both substantial and durable weight loss. This article briefly reviews the history of pharmacotherapy for obesity before focusing on the clinical trial evidence for the use of the GLP-1 agonist liraglutide as a weight loss agent and comparing its efficacy with other emerging drug therapies for obesity. Twit Text FOAVip The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity ????Ther Adv Chronic Dis http://www.kidney.de/pget.php?&tw=1&pmid=26977279 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26977279 #FOAvip English Wikipedia <ref>{{Cite pmid|26977279}}</ref> The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity #MMPMID26977279 Crane J; McGowan B Ther Adv Chronic Dis 2016[Mar]; 7 (2): 92-107 PMID26977279show ga There is a global obesity epidemic that will continue to be a financial burden on healthcare systems around the world. Tackling obesity through diet and exercise should always be the first intervention, but this has not proved to be effective for a large number of patients. Pharmacotherapeutic options have been limited and many previously available drugs have been withdrawn due to safety concerns. Currently, only bariatric surgery has the capability to induce both substantial and durable weight loss. This article briefly reviews the history of pharmacotherapy for obesity before focusing on the clinical trial evidence for the use of the GLP-1 agonist liraglutide as a weight loss agent and comparing its efficacy with other emerging drug therapies for obesity. äThe GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity (epmc).pdf DeepDyve Pubget Overpricing